TOP > 外国特許検索 > DRUG DELIVERY COMPOSITION

DRUG DELIVERY COMPOSITION

Foreign code F200010249
File No. AF30-05WO
Posted date 2020年10月30日
Country 世界知的所有権機関(WIPO)
International application number 2020JP014131
International publication number WO2020203816
Date of international filing 令和2年3月27日(2020.3.27)
Date of international publication 令和2年10月8日(2020.10.8)
Priority data
  • 特願2019-069029 (2019.3.29) JP
Title DRUG DELIVERY COMPOSITION
Abstract A drug delivery composition comprising an acid-resistant cell, said acid-resistant cell enclosing a drug therein. An acid-resistant cell enclosing a drug therein, wherein the drug is localized in a sac-like membrane structure of the acid-resistant cell.
Outline of related art and contending technology BACKGROUND ART
In animals with gastrointestinal tract, including humans, ingested from the mouth is sent to the stomach through the esophagus. For example, in oral administration of a drug, especially when the drug contains peptide or protein as a main component, the drug is highly likely to be enzymatically decomposed in the stomach. Also, since the inside of the stomach is strongly acidic, there is a concern that even a drug of a low molecular weight compound is non-enzymatically degraded in the stomach. In addition, even when the acidic compound is desired to be absorbed in the intestine, the acidic compound may be absorbed in the stomach. Therefore, oral administration using capsules that do not dissolve in the stomach but dissolve in the intestine is useful.
Methods of achieving delivery of drugs to the intestines include Technology (, Non-Patent Document 1), which is called bilosome, utilizing the nature that protein B introduced into lipid is stable in the stomach; Rice vaccines (Non-Patent Document 2) utilizing the fact that protein bodies, which are organelles of rice, exhibit resistance to digestive enzymes, or spores vaccines (Non-Patent Document 3) utilizing spores resistant to digestive enzymes, temperature changes, and pH changes are known.
As an object of industrial oral vaccines, yeast is utilized. For example, Patent Document 1 describes an oral vaccine in which an antigenic protein is expressed in yeast cells. Patent Document 1 shows that the yeast cells are lyophilized to digest and degrade in the ileum without digesting in the stomach and jejunum, but release of antigenic protein from yeast depends on the function of digestive enzyme in the small intestine. Patent Document 2 suggests that immunity is induced by transmucosal/oral administration of a yeast strain incorporating an exogenous gene, but also describes that proteins derived from yeast used have antigenic properties.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • Inventor
  • FUJIWARA Takayuki
  • HIROOKA Shunsuke
  • MIYAGISHIMA Shin-ya
  • OMATSU Tsutomu
IPC(International Patent Classification)
Reference ( R and D project ) CREST Creation of Basic Technology for Improved Bioenergy Production through Functional Analysis and Regulation of Algae and Other Aquatic Microorganisms AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close